Ed Ha

Ed Ha has over 20 years of experience in the field of medicinal chemistry. Ed began their career in 1998 as a Medicinal Chemist at Cytokinetics. In 2000, they joined Genentech, Inc. as an Antibody Drug Conjugate & Small Molecule Process Development Chemist. Here, they were responsible for scale-up and process development of small molecule candidates for the Genentech oncology pipeline. Ed also worked on the DM-1-SMCC side and was involved in reagent validation and metabolite synthesis. In addition, they were part of the Antibody Drug Conjugate Program and was involved in parallel synthesis of drugs and linkers. In 2011, they moved to Igenica Biotherapeutics as an Antibody Drug Conjugate Chemist, where they developed drug-linker strategies towards ADCs with a wide therapeutic window. In 2015, they joined Solstice Biologics as an Antibody RNA Conjugates, where they worked on site-specific and homogeneous bioconjugation of low DAR/nucleic acid payloads. In 2018, they joined Angiex as a Founding Principal Scientist - Head of Chemistry & Bioconjugation, where they worked on tumor-specific-vasculature and tumor cell unicorn. In 2021, they joined Angiex Inc. as the Founding Senior Director of ADC Innovation. Most recently, in 2022, they joined Iksuda Therapeutics as the Head of ADC Innovation.

Ed Ha studied Chemistry at the University of California, Los Angeles, and Washington University in St. Louis.